| 1. |
|
|
| 2. |
|
|
| 3. |
- Akrawi, Delshad, et al.
(författare)
-
End stage renal disease risk and neighbourhood deprivation: A nationwide cohort study in Sweden.
- 2014
-
Ingår i: European Journal of Internal Medicine. - : Elsevier BV. - 1879-0828 .- 0953-6205. ; 25:9, s. 853-859
-
Tidskriftsartikel (refereegranskat)abstract
- Chronic kidney disease has been associated with socioeconomic disparities and neighbourhood deprivation. We aimed to determine whether there is an association between neighbourhood deprivation and end stage renal disease (ESRD), and whether this association is independent of individual-level sociodemographic factors and comorbidities.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Belmatoug, Nadia, et al.
(författare)
-
Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe
- 2017
-
Ingår i: European Journal of Internal Medicine. - : Elsevier BV. - 0953-6205. ; 37, s. 25-32
-
Forskningsöversikt (refereegranskat)abstract
- Purpose: In Gaucher disease, diminished activity of the lysosomal enzyme, acid β-glucosidase, leads to accumulation of glucosylceramides and related substrates, primarily in the spleen, liver, and bone marrow. Eliglustat is an oral substrate reduction therapy approved in the European Union and the United States as a first-line treatment for adults with type 1 Gaucher disease who have compatible CYP2D6 metabolism phenotypes. A European Advisory Council of experts in Gaucher disease describes the characteristics of eliglustat that are distinct from enzyme augmentation therapy (the standard of care) and miglustat (the other approved substrate reduction therapy) and recommends investigations and monitoring for patients on eliglustat therapy within the context of current recommendations for Gaucher disease management. Results: Eliglustat is a selective, potent inhibitor of glucosylceramide synthase, the enzyme responsible for biosynthesis of glucosylceramides which accumulate in Gaucher disease. Extensive metabolism of eliglustat by CYP2D6, and, to a lesser extent, CYP3A of the cytochrome P450 pathway, necessitates careful consideration of the patient's CYP2D6 metaboliser status and use of concomitant medications which share metabolism by these pathways. Guidance on specific assessments and monitoring required for eliglustat therapy, including an algorithm to determine eligibility for eliglustat, are provided. Conclusions: As a first-line therapy for type 1 Gaucher disease, eliglustat offers eligible patients a daily oral therapy alternative to biweekly infusions of enzyme therapy. Physicians will need to carefully assess individual Gaucher patients to determine their appropriateness for eliglustat therapy. The therapeutic response to eliglustat and use of concomitant medications will require long-term monitoring.
|
|
| 9. |
- Bengtsson, Mariette, et al.
(författare)
-
Anxiety in close relationship is higher and self-esteem lower in patients with irritable bowel syndrome compared to patients with inflammatory bowel disease
- 2013
-
Ingår i: European journal of internal medicine. - : Elsevier. - 0953-6205 .- 1879-0828. ; 24:3, s. 266-272
-
Tidskriftsartikel (refereegranskat)abstract
- Background Previous research has suggested an interaction between personality factors and inflammatory bowel disease (IBD) as well as irritable bowel syndrome (IBS). We therefore aimed to elucidate differences in psychological and coping functioning between patients with IBD and IBS, and to assess the relationship of disease activity with these functions. Methods Seventy-four patients with IBD (mean age 43 ± 17 years, range 18–82 years) and 81 patients with IBS (mean age 37 ± 12 years, range 21–66 years) completed the questionnaires; Rosenberg Self-Esteem Scale, Toronto Alexithymia, Experiences in Close Relationships, and Sense of Coherence. Disease activity was evaluated either by the Harvey-Bradshaw index, the Simple Clinical Colitis Activity Index, or the Visual Analogue Scale for Irritable Bowel Syndrome. Results The study revealed that patients with IBS had higher degree of anxiety in close relationships than patients with IBD (p = 0.003), and lower self-esteem (p = 0.001). No other statistical differences between the whole groups IBS and IBD or between subgroups were seen. Conclusions The fact that patients with IBS seem to have higher levels of anxiety in relationships and lower self-esteem could influence the way the patient deal with the disease and how the communication with health care professionals works out. A higher awareness of the importance of past negative life events should be taken into consideration. Whether the disease or the personal traits are the primary event should be addressed in future research.
|
|
| 10. |
- Bengtsson, Mariette, et al.
(författare)
-
The brief Visual Analogue Scale for Irritable Bowel Syndrome questionnaire can be used to evaluate psychological well-being in patients with irritable bowel syndrome
- 2013
-
Ingår i: European journal of internal medicine. - : Elsevier. - 0953-6205 .- 1879-0828. ; 24:7, s. e82-e83
-
Tidskriftsartikel (refereegranskat)abstract
- Abstract Objective: The questionnaire Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS) has been validated in measuring gastrointestinal symptoms and psychological well-being in patients with IBS. The aim of this study was to additional evaluate the items of VAS-IBS, and to examine correlations in the items measuring psychological well-being and intestinal symptoms´ influence on daily life to attachment in close relationships, self-esteem and coping. Methods: Eighty-one patients with IBS completed VAS-IBS with five VAS items for each gastrointestinal symptom, one item for the psychological well-being, and one item for the intestinal symptoms´ influence on daily life. They also completed the questionnaires Experiences in Close Relationships, the Rosenberg Self-Esteem Scale, and the Sense of Coherence. Correlations between the questionnaires and differences between subgroups were examined. Results: The rating of the item psychological well-being as poor well-being, correlated to a high degree of anxiety in close relationships (rs = -0.293, p = 0.008), low self-esteem (rs = 0.487, p = 0.000), and reduced coping (rs = 0.579, p = 0.000). Psychological well-being correlated to the intestinal symptoms´ influence on the patients´ daily life (rs = 0.515, p = 0.000). Conclusions. By this easy-to-use and brief VAS-IBS questionnaire, the health care professionals get a lot of information not only about physical symptoms, but also about the patient´s psychological well-being.
|
|
